Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
A Potential New Indication Could Expand an Existing Product
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced its first European participant in the ReVeRA-301 Phase 3 trial on October 9, 2026. The study evaluates etripamil nasal spray for atrial fibrillation with rapid ventricular rate, targeting approximately 150 treated patient events. The medicine is already FDA-approved as CARDAMYST for a different condition, paroxysmal supraventricular tachycardia.
The bullish thesis centers on expanding the commercial opportunity around an existing medicine. Successful development could give the company another indication to market, potentially making its commercial infrastructure more productive. Geographic expansion of enrollment supports trial execution, while the existing approval provides experience with the product in a separate patient population.
The next meaningful evidence is clinical. The trial’s primary endpoint measures ventricular-rate reduction within 30 minutes, and management is pursuing a single-study supplemental application pathway. Neither that strategy nor enrollment guarantees approval. Investors should watch recruitment, safety, efficacy and funding together: a successful program creates greater shareholder value when the company can finance it without excessive dilution.
YOU MUST READ THIS: Top 10 Healthcare Stocks Under $10 to Watch Now
Disclosure: No material interests to disclose. This article was originally published on BioTech HealthX.
